Further investigations should help to clarify the relative value of FDHT-PET vs. PSMA-PET imaging in guiding therapies for prostate cancer, though it is likely that both will have distinct roles to play, as will FDG-PET [185,188,189]. The gene discussed is FOLH1; the disease is prostate cancer.